16,100 reports of this reaction
14.3% of all DEXLANSOPRAZOLE reports
#1 most reported adverse reaction
CHRONIC KIDNEY DISEASE is the #1 most commonly reported adverse reaction for DEXLANSOPRAZOLE, manufactured by Takeda Pharmaceuticals America, Inc.. There are 16,100 FDA adverse event reports linking DEXLANSOPRAZOLE to CHRONIC KIDNEY DISEASE. This represents approximately 14.3% of all 112,812 adverse event reports for this drug.
Patients taking DEXLANSOPRAZOLE who experience chronic kidney disease should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
CHRONIC KIDNEY DISEASE is a frequently reported adverse event for DEXLANSOPRAZOLE, accounting for a significant proportion of all reports.
In addition to chronic kidney disease, the following adverse reactions have been reported for DEXLANSOPRAZOLE:
The following drugs have also been linked to chronic kidney disease in FDA adverse event reports:
CHRONIC KIDNEY DISEASE has been reported as an adverse event in 16,100 FDA reports for DEXLANSOPRAZOLE. This does not prove causation, but indicates an association observed in post-market surveillance data.
CHRONIC KIDNEY DISEASE accounts for approximately 14.3% of all adverse event reports for DEXLANSOPRAZOLE, making it one of the most commonly reported side effect.
If you experience chronic kidney disease while taking DEXLANSOPRAZOLE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.